Dual Antiplatelet Therapy Plus Oral Anticoagulation: How Does Hemorrhagic Risk Impact Stent Selection?  by Giugliano, Gregory R. & Lotfi, Amir S.
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Letters to the Editor330ual Antiplatelet Therapy
lus Oral Anticoagulation:
ow Does Hemorrhagic Risk
mpact Stent Selection?
e read with great interest the article by Rogacka et al. (1). We
pplaud the authors’ attempt to clarify the time course for
emorrhagic risk to these patients. Rogacka et al. (1) showed that
ost hemorrhagic events in patients on triple therapy (TT) (dual
ntiplatelet [DAP] plus oral anticoagulation [AC]) occurred
ithin the first month of treatment and that half of these patients
ied. These hemorrhagic complications are common, real-world
ssues that impact the type of stents physicians select. Therefore,
roper interpretation of these data (to aid decision making in
veryday practice) is crucial. Unfortunately, the authors did not
ddress the risk of recurrent bleeding during the 21-month
ollow-up period in patients who suffered a major bleeding event in
he first month of TT. For example, in patients with nonvariceal
pper gastrointestinal bleeds, rebleeding can be as high as 20% (2).
t is unclear whether this study censored patients after the first
leeding event or if their TT was altered. Because current
merican College of Cardiology/American Heart Association
ecommendations now call for a minimum of 12 months DAP
herapy after drug-eluting stent (DES) implantation, if DES are
sed in patients requiring AC, this then commits such patients to
2 months of TT (3). As Rogacka et al. (1) reported, most
leeding occurs in the first month of TT, so the likelihood for
ecurrent hemorrhagic complications in the DES-treated patient
n AC is probably significant over the subsequent 11 months
nless the therapy is reduced. Certainly, early cessation of DAP
herapy after DES implantation should be avoided because it
redisposes to stent thrombosis, thus leading to a clinical
uandary.
We believe that this article may lead interventionalists to come
o one of two very disparate conclusions in an attempt to determine
tent choice in these patients: 1) The DES are more reasonable in
uch patients because the bleeding events occurred in the first
onth and therefore no difference in bleeding between DES-
reated or bare-metal stent (BMS)-treated patients was found.
herefore, reducing target lesion revascularization becomes the
ost important issue. 2) The BMS are more reasonable in such
atients because the TT predisposing to bleeding complications
ill be minimized to only 1 month, thereby reducing the recurrent
leeding risk.
We think that conclusion 1 would be erroneous given the lack
f data regarding recurrent bleeding events, alteration of TT, and
tent thrombosis. At our institution, we prefer BMS in patients
ho require long-term oral AC. Although their risk of bleeding
uring the first month may be no different if treated with DES,
heir risk of bleeding over the next 11 months should be less
ecause we routinely stop clopidogrel 1 month after BMS implan-
ation and treat with 81 mg aspirin daily to reduce bleeding risk. when DES are used, the option to cease clopidogrel after the first
onth or after an early bleeding event may be dangerous and
ay place patients at risk for stent thrombosis. Therefore, we feel
MS should be the default stent type in patients requiring chronic
ral AC.
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eply
e thank Drs. Ruiz-Nodar, Marìn, Lip, Giuliano, and Lotfi for
heir interest in our work (1). Our study was conceived to approach
he growing problem of patients necessitating chronic anticoagu-
ation who undergo percutaneous coronary intervention (PCI)
rocedures with stent implantation. We retrospectively analyzed
ur computer database, retrieved the data of the patients, and
ontacted the patients. Of course, we agree with Dr. Ruiz-Nodar
nd colleagues that the major limitation of the study is the small
umber of the patients (n  127) analyzed and its retrospective
haracter. Because of the heterogeneity of the patients on chronic
nticoagulation, the elevated risk of thromboembolic events for the
ajority of pathologies that require this type of treatment, and the
ell-documented risk of stent thrombosis if a dual antiplatelet
egiment is not observed, the randomization may be particularly
ifficult, if not impossible.
We read carefully the study of Ruiz-Nodar et al. (2), which is
he largest published study examining the problem of the anti-
latelet and anticoagulation regimen in patients with atrial fibril-
ation (AF). The differences in the outcome between this article
nd our study (major adverse cardiovascular events 32.3% vs.
3.6% and major bleeding 12.3% vs. 3.7%, respectively) probably
erive from the fact that we analyzed various subgroups of patients
ho need chronic anticoagulation (AF, valve prostheses, left
